Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04979897
Other study ID # 2020-78
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 5, 2020
Est. completion date February 2, 2022

Study information

Verified date July 2021
Source Universidad del Desarrollo
Contact Felipe González-Seguel, MSc
Phone 989540683
Email feligonzalezs@udd.cl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Intensive care unit (ICU) survivors and their families frequently present mental, cognitive and physical impairments lasting years. The ongoing pandemic could affect the duration, variety, and severity of these impairments. Our aim is to determine the impact of the COVID-19 pandemic on the physical, mental, and cognitive health of survivors, the experience of their families and their treating healthcare professionals in the long-term. This is a prospective, multicentre, mixed-methods cohort study in seven Chilean ICUs. The perceptions of family members regarding the ICU stay and the later recovery will be explored 3 months after discharge. Health care professionals will be invited to discuss the challenges faced during the pandemic using semi-structured interviews.


Recruitment information / eligibility

Status Recruiting
Enrollment 450
Est. completion date February 2, 2022
Est. primary completion date November 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (=18 years old) - Mechanically ventilated for at least 48 hours Exclusion Criteria: - Unable to walk independently 2 weeks prior to ICU admission (with or without a gait aid) - S5q < 5 or CAM-ICU positive within 72 hours after ICU discharge - Patient who do not understand or speak Spanish - Patient unable to communicate verbally - Burn or severe trauma as admission diagnosis - Any neurological disorder (i.e. spinal cord injury, stroke and brain tumours) as admission diagnosis - Transferred to a non-participating study centre before ICU discharge assessment - Recent prolonged hospital stay (extended by more than 3 months)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Intensive care unit stay during the COVID-19 pandemic
Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open [close] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study

Locations

Country Name City State
Chile Hospital Regional Dr. Leonardo Guzmán de Antofagasta Antofagasta
Chile Hospital San Pablo de Coquimbo Coquimbo
Chile Clínica Alemana de Santiago Santiago
Chile Clínica BUPA Santiago
Chile Clínica INDISA Santiago
Chile Hospital del Salvador Santiago
Chile Hospital Metropolitano Santiago

Sponsors (8)

Lead Sponsor Collaborator
Universidad del Desarrollo Clinica Alemana de Santiago, Clínica BUPA, Clínica INDISA, Hospital del Salvador, Hospital Metropolitano, Hospital Regional Dr. Leonardo Guzmán de Antofagasta, Hospital San Pablo de Coquimbo

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Other Consent rate Number of patients who agreed to participate divided by the number of patients who meet selection criteria Every month during one year
Other Cohort retention rate Number of patients who can be contacted and evaluated Every month during one year
Primary World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) The WHODAS 2.0 is a self-reported disability questionnaire based on the International Classification of Functioning, Disability, and Health (ICF). It includes 36 questions, organised under six domains (cognition, mobility, self-care, getting along, life activities and participation). Each question must be answered based on the perceived difficulty for performing activities using a 5-point scale (none, mild, moderate, severe and extreme) 6 months after the ICU discharge
Secondary Clinical Frailty Scale The CFS evaluates specific domains including physical functioning, activities of daily living (ADL), instrumental ADL, assistance for personal care, comorbidities, and cognition to generate a frailty score using a 9-point scale ranging from 1 (very fit) to 9 (terminally ill). A score greater than 4 is considered fragile Within 72 hours from ICU discharge
Secondary Medical Research Council Sum Score (MRC-SS) standardised examination of six muscle groups bilaterally (i.e. shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension and dorsiflexion) Within 72 hours from ICU discharge
Secondary Functional Status Score for the Intensive Care Unit (FSS-ICU) The FSS-ICU is a mobility instrument to score the level of physical assistance required when performing five functional activities: rolling, transfer from supine to sit, sitting at the edge of the bed, transfer from sitting to stand, and walking Within 72 hours from ICU discharge
Secondary Montreal Cognitive Assessment-Blind (MoCA blind) The MoCA blind is a cognitive screening tool designed to detect cognitive dysfunction in five areas: memory, attention, language, abstraction and orientation. It requires 5 minutes to be completed Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge
Secondary Hospital Anxiety and Depression Scale (HADS) The HADS is an interviewer or self-administered questionnaire designed to identify anxiety and depressive symptoms in a wide variety of in-hospital patients, which requires between 2 and 5 minutes to be completed Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge
Secondary Impact of Events Scale-Revised (IES-R) The IES-R is an interviewer or self-administered questionnaire designed to measure the subjective distress caused by traumatic events that has been validated for critical illness survivors Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge
Secondary European Quality of Life Health Questionnaire (EQ-5D-3L) The EQ-5D-3L is an interviewer or self-administered questionnaire of health status or health-related quality of life, including five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression and global health state 3 months, and 6 months after the ICU discharge
Secondary Employment status The employment status will be evaluated using tailored questions regarding current occupation, working hours, and any changes to their employment situation as it has been used elsewhere Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge
Secondary Survival Number of patients who survived Within 72 hours from ICU discharge, 3 months, and 6 months after the ICU discharge
Secondary Actigraphy To measure sedentary behaviour and physical activity 6 months after the ICU discharge
Secondary Global Physical Activity Questionnaire (GPAQ) To measure sedentary behaviour and physical activity 6 months after the ICU discharge
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3

External Links